Biotech fund closes USD100m raise
Categories: Hi-Tech
Arkin Capital, a Tel Aviv–based investment group active across healthcare, technology, real estate, and financial assets, closed its third dedicated biotech fund, Arkin Bio Ventures III, at USD 100 million.
The fund will invest in early clinical and advanced pre-clinical life sciences companies, with a focus on oncology, immunology, inflammation, and rare diseases.
The strategy favors biology-driven research and clinically grounded development rather than AI-centric discovery platforms. Institutional investors include Phoenix Insurance, Clal Insurance, and Amitim Pension Funds, alongside significant capital from Arkin itself.
